For a study, researchers sought to compare postoperative inflammation in patients who received an intracanalicular dexamethasone insert or topical prednisolone following iStent or Hydrus insertion during cataract surgery. Similar short-term postoperative inflammation management was achieved with an intracanalicular dexamethasone insert or topical prednisolone after iStent and Hydrus surgery. Patients who got a dexamethasone insert following the placement of an iStent or Hydrus were included, and their results were contrasted with those of controls who received topical prednisolone. Data before surgery were logged. In month 1, data on postoperative inflammatory cells and the percentage of patients with no anterior chamber cells were gathered. Cystoid macular edema rate and postoperative intraocular pressure (IOP) measurements were made at months 1 and 3. They compared 35 eyes receiving a dexamethasone insert following iStent or Hydrus insertion to 40 eyes receiving topical prednisolone. At one month after surgery, the mean postoperative inflammatory cell for the topical group was 0.2±0.3 and 0.3±0.5 for the dexamethasone group (P=0.816). In the first postoperative month, 70% of patients in the topical group had no anterior chamber cells, compared to 75.8% in the dexamethasone group (P=0.583). Preoperative IOP was 18.8±5.5 on average for the topical group and 17.1±4.1 for the dexamethasone group (P=0.064). At months 1 and 3, the mean postoperative IOP for the topical group was 17.6±6.4 and 15.1±3.1, and for the dexamethasone group, it was 17.5±4.8 and 15.0±3.4, respectively (P=0.772 and 0.884). In each group, a single patient experienced cystoid macular edema. There was no statistically significant difference in the proportion of patients with 0 anterior chamber cells at postoperative month 1 between groups receiving intracanalicular dexamethasone insert or topical prednisolone.
- Business of Medicine
- Doctor’s Voice